Abstract
Diseases associated with arterial thrombosis or venous thrombosis are leading causes of mortality and morbidity globally. Since the 1930s, antithrombotic therapy has been the cornerstone of medical therapy for thrombotic diseases. However, the success of antithrombotic therapy has come at the cost of one of the most dreaded iatrogenic complications - bleeding. Recently, new evidence has emerged on potentially important differences between thrombosis and hemostasis, thereby raising the possibility of developing new antithrombotic drugs that do not cause bleeding.
Original language | English |
---|---|
Pages (from-to) | 1133-1135 |
Number of pages | 3 |
Journal | Circulation Research |
Volume | 121 |
Issue number | 10 |
DOIs | |
Publication status | Published - 1 Jan 2017 |
Keywords
- Acute coronary syndromes
- Anticoagulants
- Aspirin
- Fibrin
- Hemorrhage
- Platelets
- Thrombosis